ReportWire

Tag: Moderna

  • Blood Donations from COVID-19 Vaccine Recipients Are Safe, Contrary to Online Claims

    Blood Donations from COVID-19 Vaccine Recipients Are Safe, Contrary to Online Claims

    [ad_1]

    SciCheck Digest

    People vaccinated with an authorized or approved COVID-19 vaccine can donate blood immediately after receiving a shot if they’re feeling well. Social media posts distort a question from the American Red Cross to baselessly claim the vaccines are unsafe.


    Full Story

    Nearly two years after related claims about COVID-19 vaccination and blood donation first surfaced, posts on social media are now pointing to a blood donation screening question to falsely suggest the vaccines are unsafe.  

    Multiple Feb. 20 posts shared a screenshot of a question included in RapidPass, a pre-donation tool the American Red Cross uses to streamline the blood donation process. The question asks if a person has “EVER had a Coronavirus (COVID-19) vaccine.” Those who answer “yes” are told to call the Red Cross “to determine if this will affect” their eligibility to donate. The posts incorrectly imply the question is new and could mean the vaccines are not safe.

    [ad_2]

    FactCheck.org

    Source link

  • Moderna soars on analyst upgrade | Entrepreneur

    Moderna soars on analyst upgrade | Entrepreneur

    [ad_1]

    Moderna (NASDAQ: MRNA) saw its stock surge 13% after Oppenheimer & Co. (NYSE: OPY) analyst Hartaj Singh upgraded the stock to “outperform” and predicted five product approvals by 2026. This comes despite a dismal 2023 for the company, marked by declining COVID-19 vaccine sales and investor concerns about pipeline progress.

    Moderna Inc. is a pioneering biotechnology company founded in 2010 with its headquarters in Cambridge, Massachusetts. They specialize in developing mRNA-based therapeutics and vaccines, including their flagship Spikevax COVID-19 vaccine, the first mRNA COVID vaccine. CEO Stéphane Bancel leads the company, which boasts a market capitalization of $42.51 billion and employs over 3500 people worldwide.

    Decoding Moderna’s post-pandemic playbook

    Moderna’s core business revolves around its mRNA platform technology. This biotechnology breakthrough instructs cells to produce specific proteins for therapeutic or preventative purposes. This technology has been applied to develop personalized cancer vaccines and vaccines for infectious diseases like COVID-19 and RSV. Despite COVID-19 vaccine sales being their current revenue driver, the company’s future hinges on its diverse pipeline of new products.

    More than just a shot in the arm

    Moderna’s recent stock surge isn’t just a blip on the financial radar. It’s a resounding vote of confidence in the company’s future, fueled by a burgeoning pipeline with promising candidates. Oppenheimer & Co.’s bullish outlook is rooted in three game-changing possibilities:

    The RSV savior

    Respiratory syncytial virus (RSV) is a common respiratory infection that can be deadly for infants and older adults. While most children encounter it before age 2, some experience severe complications, leaving a significant unmet medical need. With a potential approval date as early as April 2024, this vaccine could be a lifesaver, protecting those most vulnerable from a potentially devastating illness.

    The flu fighter

    Seasonal flu strikes fear into the hearts of millions every year, disrupting lives and clogging healthcare systems. Current vaccines offer decent protection, but their effectiveness wanes over time, requiring annual booster shots. Moderna’s flu vaccine candidate takes a different approach, aiming for broader and more durable protection. The hope is that a single shot could shield you from multiple flu strains for extended periods, significantly reducing the burden of this annual battle. That’s the potential Moderna’s flu vaccine holds.

    The cancer warriors

    Cancer, in its many forms, remains a formidable foe. But personalized cancer vaccines, tailored to each patient’s unique tumor profile, could be a game-changer. Moderna is pushing the boundaries here, developing vaccines targeting melanoma and other cancers. Think of it as training your immune system to recognize and attack your specific cancer cells, turning your body into a powerful defense system. This is truly personalized medicine at its finest, and the potential to save lives is immense.

    Why 2024 could be Moderna’s year

    The Oppenheimer upgrade came following a challenging year for Moderna in 2023. COVID-19 vaccine sales peaked, and concerns about the company’s pipeline progress weighed on the stock. However, analysts expect a turnaround in 2024 and beyond as new products launch and COVID-19 booster education efforts increase vaccine distribution.

    Moderna’s stock surge reflects renewed analyst and investor confidence in the company’s long-term potential. The potential approval of RSV and flu vaccines in the near future could inject significant revenue streams, while progress on cancer vaccines offers long-term growth prospects. Additionally, declining operating expenses and a potential rebound in COVID-19 booster sales in 2025 could further bolster the company’s financial health.

    A rising tide lifts all boats

    The far-reaching impact of Moderna’s recent surge goes beyond the numbers on a ticker. This positive news isn’t just a boon for the company itself, it is a splash of hope for the broader biotechnology industry and countless patients worldwide. Here’s how:

    Moderna

    The analyst upgrade and stock surge act as a powerful validation of the company’s pipeline strategy. Investors are voting with their wallets, expressing confidence in the game-changing potential of the RSV, flu and cancer vaccines in development. This newfound trust can unlock doors to further investment, fueling even more research and accelerating the path to bringing these innovations to market.

    Biotech industry

    Moderna’s success with mRNA technology isn’t just a win for one company, it is a beacon of light for the entire medical sector. Their pioneering work paves the way for broader adoption and exploration of this revolutionary technology by other research teams and companies. This could lead to a new wave of innovation, tackling previously untouchable diseases and pushing the boundaries of what’s possible in healthcare.

    Customers

    Ultimately, the true beneficiaries of Moderna’s pipeline lie in the potential health benefits for millions worldwide. Imagine infants and older adults protected from the dangers of RSV, thanks to a readily available vaccine. Picture a future where seasonal flu becomes a memory, thanks to a more durable and effective vaccine. And envision the hope offered by personalized cancer vaccines, empowering patients’ immune systems to fight their unique tumor profiles. These are just glimpses of the potential impact on individual lives and public health.

    While challenges remain, including potential delays in product approvals and competition within the vaccine market, Moderna’s recent upgrade and pipeline progress signal a possible shift in its fortunes. If the company successfully executes its strategy, it could regain its place as the leader in the biotech industry and deliver life-changing therapies to patients worldwide.

    [ad_2]

    Jeffrey Neal Johnson

    Source link

  • Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue

    Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue

    [ad_1]

    Updated Oct. 17, 2023 2:47 am ET

    Lonza Group warned that its profitability will take a hit next year from losing revenue from an agreement with Moderna and the risk of a smaller business with Kodiak Sciences.

    Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

    [ad_2]

    Source link

  • NIO, Moderna, Block, U.S. Steel, and More Stock Market Movers

    NIO, Moderna, Block, U.S. Steel, and More Stock Market Movers

    [ad_1]


    • Order Reprints

    • Print Article

    [ad_2]

    Source link

  • Cancer, Heart Disease Vaccines ‘Ready By End Of Decade’

    Cancer, Heart Disease Vaccines ‘Ready By End Of Decade’

    [ad_1]

    Medical experts at Moderna say they are confident that groundbreaking new vaccines for cancer, cardiovascular and autoimmune diseases, and other conditions will be ready by 2030 due to cutting-edge research into developing personalized mRNA vaccines. What do you think?

    “Imagine not wanting to die.”

    Leo Guichard, Furniture Assembler

    “I’m sure we can come up with new ways to kill people to pick up the slack.”

    Laszlo Sullivan, Narcotics Importer

    “I thought there were already vaccines that caused those diseases.”

    Grace Lee, Hologram Tester

    [ad_2]

    Source link

  • Sanders targets drug companies over COVID-19 vaccine price hikes, high prescription costs

    Sanders targets drug companies over COVID-19 vaccine price hikes, high prescription costs

    [ad_1]

    Vermont Sen. Bernie Sanders took aim at pharmaceutical companies on Sunday over upcoming price hikes for COVID-19 vaccines and high prescription drug prices more broadly, telling “Face the Nation” that he believes there is room for bipartisanship to bring down costs for working class Americans. 

    The independent senator recently called on Moderna’s chief executive officer Stéphane Bancel to testify before the Senate Health, Education, Labor and Pensions (HELP) Committee, which he chairs. Sanders called the hearing after the company suggested it would quadruple the price of COVID-19 vaccines once the shots transition to the private market.

    On Sunday, Sanders noted that U.S. gave Moderna billions of dollars to develop its vaccine. U.S. officials have said stockpiles of government-bought vaccines could run out by this summer.

    “What happens after the government stockpile of the vaccine expires? These guys say, we’re going to quadruple the price of the vaccine,” Sanders said. “Truth is, [the] pharmaceutical industry is enormously greedy, charging us outrageously, uncontrollably high prices. We’ve got to deal with that, as chairman of the relevant committee, I intend to do what I can.”

    Last week, Bancel agreed to testify before the Senate HELP committee during a hearing in March. One day later, Moderna said it would develop a program to ensure that uninsured and underinsured people can receive the vaccines at no cost. The vaccines will also remain free to those with insurance, as required by the Affordable Care Act. Pfizer and BioNTech have also confirmed their plans to hike vaccine prices to at least $110 per dose, which is more than triple the cost per shot that the Biden administration paid for a bulk purchase of COVID-19 boosters in the summer of 2022.

    Sanders said on Sunday that members of the HELP committee “want to take a look at” Moderna’s patient assistance program and called it “a step in the right direction.” Still, he underscored the need for decisive action in Congress as pharmaceutical companies continue to initiate price hikes that often make health care and prescription medications unaffordable and inaccessible.

    The senator, whose upcoming book “It’s OK to Be Angry about Capitalism” examines the growing divide between the wealthy and the working class, noted that “one out of four people in American cannot afford … the drugs that their doctors prescribe,” while roughly two-thirds are living paycheck to paycheck. Sanders additionally pointed to stark disparities in cost for the same medications in countries with public health systems, like Canada, compared with the U.S.

    “You tell me why we pay 10 times more for some drugs that are sold in the United States compared to say to Canada or to other countries, while year after year, the pharmaceutical industry makes tens of billions of dollars in profits, pays their CEOs exorbitant salaries,” Sanders said. 

    “So of course, we want the drug companies to do the research and development,” he continued. “By the way, taxpayers of this country spent $45 billion a year through the NIH to help with that research and development, including Moderna and the vaccine.”

    When asked if he sees avenues for bipartisan agreement on prescription drug costs in Congress, Sanders responded, “Yes, I do.”

    He cited polling of Republicans that showed high prescription drug costs were “a major priority they were concerned with,” and said he believes laws like the Inflation Reduction Act, as well as legislative proposals, can form “the basis for bipartisan work.” The Inflation Reduction Act, which President Biden signed into law in August of last year, reformed how Medicare sets drug prices. Advocates have said it could act as a guide and predecessor for further, broader legislation regulating the cost of prescription drugs.

    “So I think we have the basis for bipartisan work, to tell the pharmaceutical industry that they really have got to stop ripping off the American people. A number of ways you could do it,” Sanders said on Sunday. “The Inflation Reduction Act started by having Medicare negotiate prices with the pharmaceutical industry. Doesn’t kick in for a few years, I think we should expedite that.

    “Number two, of all people, my good friend, Donald Trump, all right, who I disagree with on everything, had the idea that maybe Medicare should not pay prices higher than the average of what countries around the rest of the world are paying. That’s a good idea and we want to pursue that as well,” he continued. “And there’s the concept of reimportation. … That simply says if you can buy a drug in Canada, same drug but one-tenth of the price, passes FDA specifications, it should be sold in this country at a lower price.

    [ad_2]

    Source link

  • Moderna to offer free COVID vaccine shots to uninsured after emergency ends

    Moderna to offer free COVID vaccine shots to uninsured after emergency ends

    [ad_1]

    Ask Dr. Agus: COVID policies, Ozempic & more


    Ask Dr. Agus: COVID-19 public health emergency to end in May

    04:00

    Moderna will offer free COVID-19 vaccines for “uninsured or underinsured people,” the company announced Wednesday, pledging to ensure continued access to the shots after the public health emergency ends in May and government-bought supplies run out.

    “Moderna’s COVID-19 vaccines will continue to be available at no cost for insured people whether they receive them at their doctors’ offices or local pharmacies. For uninsured or underinsured people, Moderna’s patient assistance program will provide COVID-19 vaccines at no cost,” the company said in a statement.

    The announcement comes as the vaccinemaker has come under scrutiny for plans to raise its price on the commercial market.

    Rivals Pfizer and BioNTech have already confirmed plans to list their COVID-19 vaccines starting at $110 per dose, more than triple the cost the Biden administration paid for a bulk purchase of updated COVID boosters last summer.

    But Democratic lawmakers have warned Moderna against pursuing the same kind of price hike, citing the federal dollars spent to subsidize the company’s development of the vaccine.

    The Senate Health, Education, Labor and Pensions Committee announced on Wednesday plans for a hearing titled “Taxpayers Paid Billions For It: So Why Would Moderna Consider Quadrupling the Price of the COVID Vaccine?” with the company’s CEO scheduled to testify.

    The Centers for Disease Control and Prevention’s Vaccines for Children program already plans to add COVID-19 vaccines to its roster of shots offered at no cost to uninsured and underinsured kids. 

    However, Congress has so far not funded the Biden administration’s request for a similar sweeping program to provide free vaccinations for adults who do not have health insurance. In lieu of that, federal health officials have said that they might rely on a patchwork of programs ranging from health centers to state and local partnerships to cover these uninsured shots.

    “We don’t have a vaccine program for the uninsured adult as we do for children. And so it would be really helpful, and we’re working now, to see how we can ensure that uninsured adults will get vaccinated,” CDC Director Dr. Rochelle Walensky told a House hearing earlier this month.

    [ad_2]

    Source link

  • Moderna Stock Takes Off on Cancer Vaccine News

    Moderna Stock Takes Off on Cancer Vaccine News

    [ad_1]



    Moderna


    stock shot up after


    Merck


    said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.

    Merck (ticker: MRK) will pay


    Moderna


    (MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.

    [ad_2]

    Source link